Biotech | March 09, 2022
Alvotech settles with AbbVie to secure US rights to Humira biosimilar
Alvotech expects AVT02 (adalimumab) will be marketed in the U.S., subject to regulatory approval, on July 1, 2023
Alvotech expects AVT02 (adalimumab) will be marketed in the U.S., subject to regulatory approval, on July 1, 2023
Investment in technology and people and a meaningful industry-academia partnership can fuel the growth of the Indian biopharma sector
JEEN’s portfolio includes a diverse range of specialized active ingredients, botanical extracts, and complexes serving functional applications for skin and hair care
According to statistics, the global inhalation drug market reached US $ 25 billion in 2020
This supply agreement provides material for the company’s planned 30-patient pilot study, and later for its planned U.S. pivotal study in spine fusion patients
The CO2 Optimization module is one of the four modules (Product Costing, BoM Management, CO2 Optimization, Supplier Strategy) within the entire NDC Simulation Suite
Meteoric Biopharmaceuticals have made rapid strides in the development of enzymes, probiotics and veterinary health products. It is seeking opportunities to scale up its growth backed by cutting edge R&D. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals spoke to Thomas C Thottathil on the way forward
Brinton Pharmaceuticals enters exclusive sales and distribution rights of Scholl foot care products including Krack cream
Company expects strong organic growth in sales, EBITDA in 2022
Brazil has the 4th largest pet market in the world with an estimated market size of BRL 1.8 billion, growing annually at 16%
Subscribe To Our Newsletter & Stay Updated
